 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Current Price	$2.18
Prev Close	$2.09
Open	$2.08
Dividend Yield	0.00%
50-Day Moving Average	$1.80
Beta	1.07
Avg. Volume	4.29M
PE Ratio	-7.60

52-Week High	$3.90
52-Week Low	$1.47
Market Capitalization	$216.91M
EPS	-$0.2868
Price to Book	3.74
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-3.91

IMMP Immutep LTD ADR

About

Feed

Fundamentals

News